Connect Biopharma announces positive preliminary Phase 2 data for rademikibart in adults with COPD
CNTB•Connect Biopharma reported positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for adults with COPD and type 2 inflammation. The company said the treatment reduced new moderate-to-severe exacerbations by 85% and hospitalizations or emergency department visits by 100% through one month.
1. Preliminary study results
Connect Biopharma said rademikibart reduced new moderate-to-severe COPD exacerbations by 85% and hospitalizations or emergency department visits for acute exacerbations by 100% through one month. The company also reported an 81% reduction in treatment failure through one month, said the treatment was well tolerated with fewer adverse events than placebo, and plans to engage the FDA on a Phase 3 program.
